Market Flux Event
SELLAS Life Sciences Raises $150 Million in Public Stock Offering as Alterity Wins FDA Alignment on Phase 3 MSA Trial
Read this in the Market Flux appSELLAS Life Sciences Group priced an underwritten public offering of 11,538,462 shares of common stock at $13.00 per share on November 18, 2026, raising gross proceeds of $150.0 million before underwriting discounts and commissions. J.P. Morgan Securities and TD Securities served as joint book-running managers for the deal, with all shares sold directly by SELLAS.
In a separate development, Alterity Therapeutics announced it has received confirmed FDA alignment on the design and registrational pathway for a Phase 3 trial of its lead asset ATH434 in Multiple System Atrophy (MSA), following the receipt of End-of-Phase 2 meeting minutes. The company said the clarity has enabled it to begin operational start-up activities in preparation for Phase 3 initiation. Alterity reported a cash balance of A$41.3 million as of September 30, 2026, a figure that includes an A$3.98 million Australian R&D Tax Incentive refund and approximately A$5.5 million net raised through the exercise of listed options.
© AI-generated summary is provided by Market Flux